Table 6 Comparison between CD38-negative and CD38-positive B-NHL patients:
From: Illuminating the impact of CD38-induced adenosine formation in B-cell lymphoma
B-NHL patients’ group | CD38 Negative | CD38 Positive | P-value | |
|---|---|---|---|---|
No. = 10 | No. = 32 | |||
Age (years) | Mean ± SD | 57.1 ± 11.52 | 52.28 ± 21.98 | 0.512• |
Range | 40–68 | 23–80 | ||
Sex | Females | 1 (10.0%) | 10 (31.3%) | 0.182* |
Males | 9 (90.0%) | 22 (68.8%) | ||
WBC (x103/ul) | Median (IQR) | 51.75 (27.3–117) | 30 (9.5–57.5) | 0.193‡ |
Range | 9.3–134 | 3.01–175 | ||
LYMPH (x103/ul) | Median (IQR) | 35 (19–103) | 24 (10–44.5) | 0.261‡ |
Range | 6–129 | 2–160 | ||
HB (g/dl) | Mean ± SD | 11.39 ± 2.62 | 8.94 ± 1.68 | 0.001• |
Range | 5.2–13.7 | 6–14 | ||
PLT (x103/ul) | Median (IQR) | 274 (233–307) | 63 (50–112) | 0.000‡ |
Range | 158–402 | 10–576 | ||
BM.LYM (%) | Mean ± SD | 59.1 ± 19.04 | 70.59 ± 23.56 | 0.169• |
Range | 21–80 | 10–95 | ||
sPD-L1 (ng/L) | Median (IQR) | 183.25 (59–522.2) | 168.92 (144.31–279.74) | 0.595‡ |
Range | 21.51–1427 | 103.4–1124 | ||
sPD-1 (ng/L) | Median (IQR) | 67.1 (37–143) | 178.63 (147–289) | 0.003‡ |
Range | 21–680 | 110–1300 | ||
sADO (ng/ml) | Median (IQR) | 504.3 (343–567) | 990.5 (742–1400.5) | 0.000‡ |
Range | 77–614 | 553–1700 | ||
Risk stratification | Low | 0 (0.0%) | 3 (9.4%) | 0.001* |
Intermediate | 10 (100.0%) | 11 (34.4%) | ||
High | 0 (0.0%) | 18 (56.3%) | ||
